NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/05/2024
Voltar para busca
Dado oficial do USPTO
JOONGKYEOM ANTIBODY THERAPY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
11/05/2024
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 35, 42
Data de depósito
16/11/2021
Data de registro
04/04/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/04/2023
Última transação
04/04/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
03
Localização do titular
KR
Examinador
CHANG, BETTY
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "JOONGKYEOM" stacked above the wording "ANTIBODY THERAPY", wherein an infinity symbol represents the letters "OO", all to the left of a stylized letter "X" and its shadow.
Titulares e representantes
Titulares
JOONGKYEOM Co., Ltd.
Representantes
Ziwen Zhu Locke Lord LLP
Classificação técnica
Classes Nice
Classe 5Classe 35Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Preparations of microorganisms for medical use; bacterial preparations for medical and veterinary use; diagnostic preparations for medical and veterinary use; cultures of microorganisms for medical and veterinary use; preparations of microorganisms for medical and veterinary use; bacteriological preparations for medical and veterinary use; biological preparations for medical purposes; diagnostic agents for medical use; medicinal diagnostic reagents; pharmaceutical preparations for diagnosis; preparations for diagnosing antibodies; pharmaceutical preparations for the treatment of antibodies
Classe 35
Wholesale store services featuring microorganisms for medical purposes; retail store services featuring microorganisms for medical purposes; wholesale store services featuring bacterial preparations for medical and veterinary use; retail store services featuring bacterial preparations for medical and veterinary use; wholesale store services featuring diagnostic preparations for medical and veterinary use; retail store services featuring diagnostic preparations for medical and veterinary use; business intermediary services relating to the matching of parties for purchase and sale of drugs for medical purposes; wholesale store services featuring drugs for medical purposes; retail store services featuring drugs for medical purposes; wholesale store services featuring medical preparations for diagnosing antibodies; retail store services featuring medical preparations for diagnosing antibodies; wholesale store services featuring medicinal diagnostic reagents; retail store services featuring medicinal diagnostic reagents; business intermediary services relating to the matching of parties for purchase and sale of medicinal diagnostic reagents; wholesale store services featuring pharmaceutical preparations for diagnosis; retail store services featuring pharmaceutical preparations for diagnosis; business merchandising display services; wholesale store services featuring pharmaceutical preparations for the treatment of antibodies; retail store services featuring pharmaceutical preparations for the treatment of antibodies; sales agency services, namely, independent sale representatives for pharmaceutical preparations for the treatment of antibodies
Classe 42
Research and development of vaccines and medicines; advisory services relating to biotechnology; research relating to biotechnology; consulting services in the fields of biotechnology; biological research; medical research in the field of crude drugs; biochemical analysis; biochemistry research services; research on adult diseases; research relating to bacteriology; research services in the fields of cancerous diseases; development of pharmaceuticals; research relating to pharmaceuticals; advisory services relating to development of pharmaceuticals; pharmaceutical products evaluation; consultancy pertaining to pharmacology; research in the field of gene analysis; genetic research; research relating to medical products; medical research services
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
14/08/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
24/07/2023
FIMP
FINAL DISPOSITION PROCESSED
24/07/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/07/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
04/04/2023
GPNX
NOTIFICATION PROCESSED BY IB
25/01/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/01/2023
PUBO
PUBLISHED FOR OPPOSITION
17/01/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/01/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/01/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/12/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/12/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/12/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/12/2022
RFNP
REFUSAL PROCESSED BY IB
14/11/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
22/10/2022
RFRR
REFUSAL PROCESSED BY MPU
21/10/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
31/08/2022
CNRT
NON-FINAL ACTION WRITTEN
30/08/2022
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
30/08/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/08/2022
CNRT
NON-FINAL ACTION WRITTEN
27/08/2022
DOCK
ASSIGNED TO EXAMINER
27/08/2022
MAFR
APPLICATION FILING RECEIPT MAILED
19/02/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
15/02/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/02/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace JOONGKYEOM ANTIBODY THERAPY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.